Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2017 · 10-Q
Revenue$611.00K$611.00K+388.8% vs Q2 2016 Net Income-$3.18M-$3.18MN/M vs Q2 2016 EPS Diluted$0.24$0.24+71.4% vs Q2 2016 Operating Income-$3,365,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-550.7%+978.9 pt vs Q2 2016
Net margin-520.9%+933.5 pt vs Q2 2016
ended Feb 28, 2017 · filed Apr 5, 2017 · 36 d after period end